Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC

Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.

Related Keywords

Germany , Japan , United States , United Kingdom , Madrid , Spain , Zurich , Züsz , Switzerland , Austria , Vienna , Wien , Manchester , Spanish , American , Mariano Provencio , Westdeutsches Tumorzentrum Essen , Masahiro Tsuboi , Wilfried Eberhardt , Isabelle Opitz , Salud Carlos , Corinne Faivre Finn , European Union Horizon , National Cancer Center Hospital , Department Of Thoracic Surgery , University Hospital Zurich , American Society Of Clinical Oncology , Twitter , University Of Manchester , Boehringer Ingelheim , Thermo Fisher , Pfizer , Astrazeneca , Spanish Lung Cancer Group , Bristol Myers Squibb , World Conference , Lung Cancer , Thoracic Radiation Oncology , Thoracic Surgery , National Cancer Center Hospital East , American Society , Clinical Oncology , Mariano Provencio Pulla , Spanish Lung Cancer , Instituto De Salud Carlos , European Union , Merck Sharp , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Nsclc , Chemotherapy , Neoplasm , Tumor , Neoadjuvant , Biologic Therapy , Immunotherapy , Lobectomy , Radiation Oncology , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Surgery , Presection , Hospitals , Inpatient Care ,